Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Gu, Dongmin ^a   Wang, Shuhong ^b   Kuiatse, Isere ^a   Wang, Hua ^a   He, Jin ^a   Dai, Yun ^c   Jones, Richard J ^a   Bjorklund, Chad C ^a   Yang, Jing ^a   Grant, Steven ^c   Orlowski, Robert Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; LENALIDOMIDE; MI 63; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; ABT-737; BIPHENYL DERIVATIVE; INDOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; MI-63 COMPOUND; NITROPHENOL; PIPERAZINE DERIVATIVE; SPIRO COMPOUND; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTOPHAGY; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; INDOLES; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; MUTATION; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; SPIRO COMPOUNDS; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907459332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103015     Document Type: Article

References (64)

1. Mahindra A, Hideshima T, Anderson KC (2010) Multiple myeloma: biology of the disease. Blood Rev 24 Suppl 1: S5-11.
2. Rajkumar SV (2011) Treatment of multiple myeloma. Nat Rev Clin Oncol 8: 479-491.
3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
4. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520.
5. Brenner H, Gondos A, Pulte D (2009) Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 94: 270-275.
6. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, et al. (2010) Longterm follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 28: 1209-1214.
7. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, et al. (2013) Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27: 226-232.
8. Anderson KC (2012) The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30: 445-452.
9. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, et al. (2013) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia.
10. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, et al. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120: 947-959.
11. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23: 1964-1979.
12. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657. (Pubitemid 351469448)
13. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, et al. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534. (Pubitemid 36182530)
14. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, et al. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076. (Pubitemid 32691956)
15. Pei XY, Dai Y, Grant S (2003) The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17: 2036-2045. (Pubitemid 37322135)
16. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, et al. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257-264. (Pubitemid 43053550)
17. Ding WX, Ni HM, Chen X, Yu J, Zhang L, et al. (2007) A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther 6: 1062-1069. (Pubitemid 46554577)
18. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, et al. (2012) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118: 4771-4779.
19. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, et al. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26: 2326-2335.
20. Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, et al. (2013) The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. Science.
21. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, et al. (2013) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4. Br J Haematol.
22. Fahraeus R, Olivares-Illana V (2013) MDM2's social network. Oncogene.
23. Quesnel B, Preudhomme C, Oscier D, Lepelley P, Collyn-d'Hooghe M, et al. (1994) Over-expression of the MDM2 gene is found in some cases of haematological malignancies. Br J Haematol 88: 415-418.
24. Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, et al. (2003) Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica 88: 529-537. (Pubitemid 36648442)
25. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, et al. (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18: 367-381.
26. Teoh G, Urashima M, Ogata A, Chauhan D, DeCaprio JA, et al. (1997) MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90: 1982-1992. (Pubitemid 27377310)
27. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, et al. (2009) Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 69: 7347-7356.
28. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848. (Pubitemid 38174664)
29. Coutts AS, Boulahbel H, Graham A, La Thangue NB (2007) Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep 8: 84-90. (Pubitemid 46043805)
30. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, et al. (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106: 3609-3617. (Pubitemid 41609200)
31. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, et al. (2009) Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 15: 7153-7160.
32. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, et al. (2010) MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 9: 936-944.
33. Zak K, Pecak A, Rys B, Wladyka B, Domling A, et al. (2013) Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Expert Opin Ther Pat 23: 425-448.
34. Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, et al. (2006) Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49: 3432-3435. (Pubitemid 43902447)
35. Shangary S, Qin D, McEachern D, Liu M, Miller RS, et al. (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 105: 3933-3938. (Pubitemid 351723502)
36. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, et al. (2011) HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118: 4140-4149.
37. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, et al. (2012) Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120: 3260-3270.
38. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, et al. (2011) Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene 30: 1329-1340.
39. Jones RJ, Gu D, Bjorklund CC, Kuiatse I, Remaley AT, et al. (2013) The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1. J Pharmacol Exp Ther 346: 381-392.
40. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, et al. (2011) Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286: 11009-11020.
41. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, et al. (2013) Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia.
42. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, et al. (1999) MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447: 5-9. (Pubitemid 29134936)
43. Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, et al. (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65: 4673-4682. (Pubitemid 40740803)
44. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, et al. (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 116: e56-65.
45. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, et al. (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109: 3489-3495. (Pubitemid 46572539)
46. Chang H, Trieu Y, Qi X, Jiang NN, Xu W, et al. (2011) Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leuk Res 35: 95-98.
47. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, et al. (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 285: 10850-10861.
48. Davids MS, Letai A (2012) Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 30: 3127-3135.
49. Lin J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8: 1235-1246. (Pubitemid 24163450)
50. Picksley SM, Vojtesek B, Sparks A, Lane DP (1994) Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9: 2523-2529. (Pubitemid 24254027)
51. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ (2012) Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther 11: 2243-2253.
52. White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12: 401-410.
53. Choi AM, Ryter SW, Levine B (2013) Autophagy in human health and disease. N Engl J Med 368: 651-662.
54. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, et al. (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 126: 121-134. (Pubitemid 44040988)
55. Crighton D, Wilkinson S, Ryan KM (2007) DRAM links autophagy to p53 and programmed cell death. Autophagy 3: 72-74. (Pubitemid 46100722)
56. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, et al. (2008) Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 10: 676-687. (Pubitemid 351772933)
57. Thakurta A, Gandhi AK, Waldman MF, Bjorklund C, Ning Y, et al. (2013) Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia.
58. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, et al. (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13: 1133-1140.
59. Ha JH, Won EY, Shin JS, Jang M, Ryu KS, et al. (2011) Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. J Am Chem Soc 133: 1244-1247.
60. Shin JS, Ha JH, He F, Muto Y, Ryu KS, et al. (2012) Structural insights into the dual-targeting mechanism of Nutlin-3. Biochem Biophys Res Commun 420: 48-53.
61. Surget S, Chiron D, Gomez-Bougie P, Descamps G, Menoret E, et al. (2012) Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 72: 4562-4573.
62. Ortega MM, Melo MB, De Souza CA, Lorand-Metze I, Costa FF, et al. (2003) A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. Ann Hematol 82: 405-409. (Pubitemid 36949791)
63. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, et al. (2008) An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112: 4235-4246.
64. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, et al. (1998) Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92: 802-809. (Pubitemid 28355463)